The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine
Abstract
Seven metabolites of venlafaxine, identified in several species, were examined for CNS pharmacological activity in rodents. The O‐desmethyl compound Wy‐45,233, which is the major metabolite in man, had the greatest preclinical activity. This metabolite exhibited an antidepressant profile (monoamine uptake blockade, reversal of reserpine hypothermia, induction of pineal β‐adrenergic subsensitivity) comparable to the parent drug, venlafaxine. This compound also inhibited serotonergic and noradrenergic firing rates like the parent compound, but with less potency. The cyclohexyl ring‐hydroxylated metabolite Wy‐47,877 and the N‐desmethyl metabolite Wy‐45, 494 were also active in reserpine hypothermia, but Wy‐45,494 was a weaker inhibitor of serotonin uptake and both metabolites were weaker inhibitors of norepinephrine uptake than Wy‐45,233. None of the seven metabolites tested exhibited significated binding at dopamine‐2, muscarinic cholinergic, α‐1‐adrenergic, histamine‐1, or opiate (μ) receptors. These results suggest that Wy‐45,233, the O‐desmethyl metabolite of venlafaxine, is an active metabolite which retains the benign side‐effect profile of venlafaxine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Muth, E. A., Haskins, J. T., Moyer, J. A., Husbands, G. E. M., Nielsen, S. T., & Sigg, E. B. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90769-0 · Cited by 374
Self-citation
Cited by
Antidepressants in the Treatment of Neuropathic Pain
Sindrup, S. H., Otto, M., Finnerup, N. B., & Jensen, T. S. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_96696601.x · Cited by 624
Sánchez, C., & Hyttel, J. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006986824213 · Cited by 429
Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Venlafaxine versus imipramine in painful polyneuropathy: A randomized, controlled trial
Sindrup, S. H., Bach, F. W., Madsen, C., Gram, L. F., & Jensen, T. S. (2003) · Neurology · doi:10.1212/01.wnl.0000058749.49264.bd · Cited by 373
Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor
Wong, E. H. F., Sonders, M. S., Amara, S. G., Tinholt, P. M., Piercey, M. F. P., Hoffmann, W. P., Hyslop, D. K., Franklin, S., Porsolt, R. D., Bonsignori, A., et al. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00291-7 · Cited by 334
Venlafaxine: A Review of its Pharmacology and Therapeutic Potential in Depression
Holliday, S. M., & Benfield, P. (1995) · Drugs · doi:10.2165/00003495-199549020-00010 · Cited by 327
Martin, S. D., Martin, E., Rai, S. S., Richardson, M. A., & Royall, R. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.7.641 · Cited by 321
Evidence of the dual mechanisms of action of venlafaxine
Harvey, A. T., Rudolph, R. L., & Preskorn, S. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.503 · Cited by 302
Venlafaxine in neuropathic pain following treatment of breast cancer
Tasmuth, T., Härtel, B., & Kalso, E. (2002) · European Journal of Pain · doi:10.1053/eujp.2001.0266 · Cited by 252
Synaptic Effects of Antidepressants
RICHELSON, E. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606002-00001 · Cited by 120
McCleane, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822020-00005 · Cited by 109
Smoking and antidepressants pharmacokinetics: a systematic review
Oliveira, P., Ribeiro, J., Donato, H., & Madeira, N. (2017) · Annals of General Psychiatry · doi:10.1186/s12991-017-0140-8 · Cited by 60
“However, the pharmacodynamical effects of this are not completely understood, though many studies point to considerably weaker inhibition of serotonin and noradrenaline reuptake pumps when compared with venlafaxine itself [34].”
BackgroundMahapatra, S., & Hackett, D. (1997) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1997.tb11434.x · Cited by 58
Abdelmawla, Langley, Szabadi, & Bradshaw (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00031.x · Cited by 58
Weikop, P., Kehr, J., & Scheel-Krüger, J. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800311 · Cited by 57
Steps Following Attainment of Remission: Discontinuation of Antidepressant
Shelton, R. C. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0404 · Cited by 43
Rickels, K., Montgomery, S. A., Tourian, K. A., Guelfi, J. D., Pitrosky, B., Padmanabhan, S. K., Germain, J.-M., Leurent, C., & Brisard, C. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c94c4d · Cited by 33
Montgomery, S. A., Fava, M., Padmanabhan, S. K., J. Guico-Pabia, C., & Tourian, K. A. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832fbb5a · Cited by 27
Metadata
- Authors
- Muth, E. A., Moyer, J. A., Haskins, J. T., Andree, T. H., & Husbands, G. E. M.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 1991-01
- Volume
- 23
- Issue
- 2
- Pages
- 191-199
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W1970421748
- Cited by
- 212
- References
- 1
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.